Put companies on watchlist
Limes Schlosskliniken AG
ISIN: DE000A0JDBC7
WKN: A0JDBC
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Limes Schlosskliniken AG · ISIN: DE000A0JDBC7 · EQS - adhoc news (20 News)
Country: Germany · Primary market: Germany · EQS NID: 1269881
18 January 2022 11:27AM

Limes Schlosskliniken AG: Preliminary financial results LIMES Group 2021 (unaudited) - Outlook 2022


DGAP-Ad-hoc: Limes Schlosskliniken AG / Key word(s): Preliminary Results/Results Forecast
Limes Schlosskliniken AG: Preliminary financial results LIMES Group 2021 (unaudited) - Outlook 2022

18-Jan-2022 / 11:27 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


DGAP-Adhoc: Limes Schlosskliniken AG:

Preliminary financial results LIMES Group 2021 (unaudited) - Outlook 2022

- Total revenue EUR 16.9m; (p. y. EUR 11.2m) +51 %

- Gross earnings (EBITDA) +5,394 kEUR; (p. y. EUR +838 kEUR)

- Operating result (EBIT) +3,505 kEUR; (p.y. EUR -427 kEUR)

- Earning before tax (EBT) +3,284 kEUR; (p. y. -693 kEUR)


Cologne, January 18, 2022: The LIMES Schlosskliniken Group was able to record a positive business performance in fiscal year 2021. Excluding the consolidation of the acquired Swiss clinic Paracelsus Recovery Group, LIMES Schlosskliniken was able to expand sales to EUR 16.9m and generate positive earnings before interest, taxes, depreciation and amortization (EBITDA) of 5,394 kEUR. The operating profit before interest (EBIT) amounts to 3,505 kEUR. Consolidated profit before taxes will be 3,284 kEUR. The business figures include 641 kEUR in depreciation and amortization for the start-up of business operations. Due to the use of loss carryforwards, only minimum taxation will apply.

For 2022, including the consolidation of the Paracelsus Recovery Group, we expect sales of EUR 27.0m (+60%). The operating result (EBITDA) is expected to amount to approximately EUR 7.6m. We anticipate an operating result (EBIT) of EUR 5.4m. The budgeted figures for the 2022 financial year already take into account the start-up losses of EUR 1.3m for the new clinc "LIMES Schlossklinik Bergisches Land". The new clinic is scheduled to start operating on September 1, 2022. After a certain start-up phase, we expect additional sales of EUR 18.0m at 80 % capacity utilization.

The LIMES Schlosskliniken Group operates high-quality private clinics in Germany for stress-related illnesses, mental and emotional disorders, such as depression, affective disorders and acute burnout conditions. The range of services is aimed at private patients, those entitled to state aid and self-payers. The LIMES Schlosskliniken Group stands for the special approach of a relationship-oriented medicine in the treatment of people with mental illnesses. In addition to top medical quality, patients are offered a unique, protected and healing environment in which they can recover holistically. Further information is available at www.limes-schlosskliniken.de.


Your contact person:
LIMES Schlosskliniken AG, Petra Kaes, Investor Relations
Tel.: 02203 / 29014-202, p.kaes@limes.care, www.limes-schlosskliniken.de

Language: English
Company: LIMES Schlosskliniken AG, Kaiser-Wilhelm-Ring 26, 50672 Köln, Germany
ISIN: DE000A0JDBC7
WKN: AOJDBC
Stock exchange Düsseldorf Freiverkehr, Primärmarkt, XETRA

End of the message


18-Jan-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Limes Schlosskliniken AG
Kaiser-Wilhelm-Ring 26
50672 Köln
Germany
ISIN: DE000A0JDBC7
WKN: A0JDBC
Listed: Regulated Unofficial Market in Dusseldorf
EQS News ID: 1269881

 
End of Announcement DGAP News Service

1269881  18-Jan-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1269881&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Limes Schlosskliniken AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.